JP Morgan Chase’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

JP Morgan Chase’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-13,999	Closed	-$141K	–	8061
2023 Q4	$141K	Buy	13,999 +1,161	+9%	+$5.27K	﹤0.01%	5580
2023 Q3	$37K	Buy	12,838 +10,573	+467%	+$38.7K	﹤0.01%	5898
2023 Q2	$8.63K	Buy	2,265 +62	+3%	+$174	﹤0.01%	6080
2023 Q1	$4K	Buy	2,203 +178	+9%	+$372	﹤0.01%	6318
2022 Q4	$5K	Sell	2,025 -1,249	-38%	-$3.83K	﹤0.01%	6179
2022 Q3	$11K	Buy	3,274 +425	+15%	+$1.38K	﹤0.01%	5950
2022 Q2	$16K	Sell	2,849 -3,212	-53%	-$9.99K	﹤0.01%	5943
2022 Q1	$14K	Buy	6,061 +1,649	+37%	+$5.62K	﹤0.01%	6149
2021 Q4	$27K	Buy	4,412 +4,331	+5,347%	+$41.6K	﹤0.01%	6140
2021 Q3	$1K	Buy	+81	New	+$956	﹤0.01%	6419

JP Morgan Chase's GRCL Position: Q1 2024 in Review

JP Morgan Chase sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 13,999 shares — an estimated $141K sold.

JP Morgan Chase first reported a position in GRCL in Q3 2021 and held it in 10 quarters. The position peaked at $141K in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

JP Morgan Chase reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
JP Morgan Chase sold 13,999 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $141K.
JP Morgan Chase first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q3 2021 and held it in 10 quarters.
JP Morgan Chase's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $141K in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.